×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: LY4006895 Phase 1 Trial - Early Alzheimer's
clinical
758 words
KG: ent-clin-01820ceb
2026-03-31
kind:clinical-trial
section:clinical-trials
state:published
disease:alzheimers
phase:phase1
Contents
LY4006895 Phase 1 Trial - Early Alzheimer's
Knowledge Graph
Related Hypotheses (12)
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
Stress Granule Phase Separation Modulators
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.44
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.39
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Show 7 more
Related Analyses (10)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · completed
Show 5 more
Related Experiments (1)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40